Imaging in its Heyday: Clinical Applications (Part II)

As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.

By Wendy Diller

In February of this year, the FDA approved the first radioimmunotherapy in the US, Idec Pharmaceuticals Corp. 's ibritumomab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business